ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Prevention Strategies for Exacerbations of Chronic Obstructive Pulmonary Disease

Bibliography link: Avdeev S. N. Prevention Strategies for Exacerbations of Chronic Obstructive Pulmonary Disease. Doctor.Ru. 2017. 10(139): 40–48.
20 October 00:00

Objective of the Review: To describe the etiology, clinical consequences, and approaches to prevention and treatment of chronic obstructive pulmonary disease (COPD) exacerbations.

Key Points: COPD is typically characterized by occasional exacerbations, which are one of the most common reasons for patients to seek emergency medical care. Frequent COPD exacerbations cause prolonged (up to several weeks) worsening of pulmonary function and gas exchange parameters, accelerate disease progression, and significantly reduce quality of life, thus entailing considerable treatment costs. Pharmacological prevention strategies for COPD include long-acting bronchodilators, inhalation corticosteroids alone or in combination with β2-agonists, phosphodiesterase type-4 inhibitors, antibiotics, and mucoactive agents.

Conclusion: Management of COPD could be improved by developing more targeted medication regimens for preventing exacerbations, even if they include currently used drugs. Non-medication prevention is not inferior to preventive medication for achieving the main goals of COPD therapy.

S. N. Avdeev — Research Institute of Pulmonology, Russian Federal Medical and Biological Agency, Moscow. Е-mail: serg_avdeev@list.ru

Доктор.ру
20 October 00:00
LITERATURE
  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of chronic obstructive pulmonary disease. Revised 2017. www.goldcopd.org (дата обращения — 31.10.2017).
  2. Gershon A. S., Dolmage T. E., Stephenson A., Jackson B. Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. COPD. 2012; 9(3): 216–26.
  3. Hurst J. R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363(12): 1128–38.
  4. Agustí A., Calverley P. M., Decramer M., Stockley R. A., Wedzicha J. A. Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. Chronic Obstr. Pulm. Dis. 2014; 1(2): 166–84.
  5. Bhowmik A., Seemungal T. A., Sapsford R. J., Wedzicha J. A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000; 55(2): 114–20.
  6. Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003; 124(5): 1743–8.
  7. Qiu Y., Zhu J., Bandi V., Atmar R. L., Hattotuwa K., Guntupalli K. K. et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 168(8): 968–75.
  8. Wilkinson T. M., Hurst J. R., Perera W. R., Wilks M., Donaldson G. C., Wedzicha J. A. et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006; 129(2): 317–24.
  9. Wedzicha J. A., Seemungal T. A. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370(9589): 786–96.
  10. Celli B. R., Barnes P. J. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29(6): 1224–38.
  11. Seemungal T., Harper-Owen R., Bhowmik A., Moric I., Sanderson G., Message S. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164(9): 1618–23.
  12. Sethi S., Evans N., Grant B. J., Murphy T. F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347(7): 465–71.
  13. Papi A., Bellettato C. M., Braccioni F., Romagnoli M., Casolari P., Caramori G. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173(10): 1114–21.
  14. Quint J. K., Donaldson G. C., Hurst J. R., Goldring J. J., Seemungal T. R., Wedzicha J. A. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur. Respir. J. 2011; 37(3): 501–7.
  15. Seemungal T. A., Donaldson G. C., Paul E. A., Bestall J. C., Jeffries D. J., Wedzicha J. A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157(5 pt.1): 1418–22.
  16. Hurst J. R., Donaldson G. C., Quint J. K., Goldring J. J., Baghai-Ravary R., Wedzicha J. A. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 179(5): 369–74.
  17. Perera W. R., Hurst J. R., Wilkinson T. M., Sapsford R. J., Müllerova H., Donaldson G. C. et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29(3): 527–34.
  18. Langsetmo L., Platt R. W., Ernst P., Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am. J. Respir. Crit. Care Med. 2008; 177(4): 396–401.
  19. Wilkinson T. M., Donaldson G. C., Hurst J. R., Seemungal T. A., Wedzicha J. A. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169(12): 1298–303.
  20. Barbera J. A., Roca J., Ferrer A., Félez M. A., Díaz O., Roger N. et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10(6): 1285–91.
  21. Casadevall C., Coronell C., Ramirez-Sarmiento A. L., Martínez-Llorens J., Barreiro E., Orozco-Levi M. et al. Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients. Eur. Respir. J. 2007; 30(4): 701–7.
  22. Hogg J. C., Chu F., Utokaparch S., Woods R., Elliott W. M., Buzatu L. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350(26): 2645–53.
  23. Wedzicha J. A., Hurst J. R. Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. Proc. Am. Thorac. Soc. 2007; 4(8): 602–5.
  24. Saha S., Brightling C. E. Eosinophilic airway inflammation in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2006; 1(1): 39–47.
  25. Siva R., Green R. H., Brightling C. E., Shelley M., Hargadon B., McKenna S. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 2007; 29(5): 906–13.
  26. Bafadhel M., McKenna S., Terry S., Mistry V., Reid C., Haldar P. et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184(6): 662–71.
  27. Hoogendoorn M., Hoogenveen R. T., Rutten-van Molken M. P., Vestbo J., Feenstra T. L. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur. Respir. J. 2011; 37(3): 508–15.
  28. Suissa S., Dell’aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67(11): 957–63.
  29. Donaldson G. C., Seemungal T. A., Bhowmik A., Wedzicha J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57(10): 847–52.
  30. Donaldson G. C., Seemungal T. A., Patel I. S., Bhowmik A., Wilkinson T. M., Hurst J. R. et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128(4): 1995–2004.
  31. Spencer S., Jones P. W. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003; 58(7): 589–93.
  32. Cote C. G., Dordelly L. J., Celli B. R. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007; 131(3): 696–704.
  33. Kanner R. E., Anthonisen N. R., Connett J. E. Lower respiratory illnesses promote FEV(1) decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am. J. Respir. Crit. Care Med. 2001; 164(3): 358–64.
  34. Vestbo J., Edwards L. D., Scanlon P. D., Yates J. C., Agusti A., Bakke P. et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365(13): 1184–92.
  35. Seemungal T. A., Donaldson G. C., Bhowmik A., Jeffries D. J., Wedzicha J. A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161(5): 1608–13.
  36. Celli B. R., Thomas N. E., Anderson J. A., Ferguson G. T., Jenkins C. R., Jones P. W. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178(4): 332–8.
  37. Donaldson G. C., Wilkinson T. M., Hurst J. R., Perera W. R., Wedzicha J. A. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171(5): 446–52.
  38. Effing T. W., Kerstjens H. A., Monninkhof E. M., van der Valk P. D. L. P. M., Wouters E. F. M., Postma D. S. et al. Definitions of exacerbations: does it really matter in clinical trials on COPD? Chest. 2009; 136(3): 918–23.
  39. Tashkin D. P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359(15): 1543–54.
  40. Calverley P. M., Anderson J. A., Celli B., Ferguson G. T., Jenkins C., Jones P. W. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356(8): 775–89.
  41. Beeh K. M., Hederer B., Glaab T., Müller A., Rutten-van Moelken M., Kesten S. et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int. J. Chron. Obstruct. Pulmon. Dis. 2009; 4: 119–25.
  42. Aaron S. D., Fergusson D., Marks G. B., Suissa S., Vandemheen K. L., Doucette S. et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008; 63(2): 122–8.
  43. Leidy N. K., Wilcox T. K., Jones P. W., Roberts L., Powers J. H., Sethi S. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am. J. Respir. Crit. Care Med. 2011; 183(3): 323–9.
  44. Anthonisen N. R., Skeans M. A., Wise R. A., Manfreda J., Kanner R. E., Connett J. E. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142(4): 233–9.
  45. Au D. H., Bryson C. L., Chien J. W., Sun H., Udris E. M., Evans L. E. et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J. Gen. Intern. Med. 2009; 24(4): 457–63.
  46. Christenhusz L. C., Prenger R., Pieterse M. E., Seydel E. R., van der Palen J. Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine Tob. Res. 2012; 14(6): 657–63.
  47. Godtfredsen N. S., Lam T. H., Hansel T. T., Leon M. E., Gray N., Dresler C. et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur. Respir. J. 2008; 32(4): 844–53.
  48. Wongsurakiat P., Maranetra K. N., Wasi C., Kositanont U., Dejsomritrutai W., Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004; 125(6): 2011–20.
  49. Walters J. A., Smith S., Poole P., Granger R. H., Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; 11: CD001390.
  50. Nichol K. L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann. Intern. Med. 1999; 130(5): 397–403.
  51. Granger R., Walters J., Poole P. J., Lasserson T. J., Mangtani P., Cates C. J. et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 4: CD001390.
  52. Alfageme I., Vazquez R., Reyes N., Muñoz J., Fernández A., Hernandez M. et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax. 2006; 61(3): 189–95.
  53. Collet J. P., Shapiro P., Ernst P. Renzi T., Ducruet T., Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am. J. Respir. Crit. Care Med. 1997; 156(6): 1719–24.
  54. Soler M., Mutterlein R., Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration. 2007; 74(1): 26–32.
  55. Cazzola M. A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Trends Med. 2006; 6(3): 199–207.
  56. Greening N. J., Williams J. E., Hussain S. F., Harvey-Dunstan T. C., Bankart M. J., Chaplin E. J. et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ. 2014; 349: g4315.
  57. Puhan M. A., Gimeno-Santos E., Scharplatz M., Troosters T., Walters E. H., Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; 10: CD005305.
  58. Miravitlles M., D’Urzo A., Singh D., Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Resp. Res. 2016; 17(1): 112.
  59. Miravitlles M., Calle M., Soler-Cataluña J. J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch. Bronconeumol. 2012; 48(3): 86–98.
  60. Goh F., Shaw J. G., Savarimuthu Francis S. M., Vaughan A., Morrison L.,Relan V. et al. Personalizing and targeting therapy for COPD: the role of molecular and clinical biomarkers. Expert Rev. Respir. Med. 2013; 7(6): 593–605.
  61. Donohue J. F., Fogarty C., Lotvall J., Mahler D. A., Worth H., Yorgancioglu A. et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 2010; 182(2): 155–62.
  62. Siler T. M., Williams J., Yegen U., Owen R, Lassen C, Kramer B. The effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment. Am. J. Respir. Crit. Care Med. 2010; 181: A4430.
  63. Halpin D. M., Vogelmeier C., Pieper M. P., Metzdorf N., Richard F., Anzueto A. Effect of tiotropium on COPD exacerbations: A systematic review. Respir. Med. 2016; 114: 1–8.
  64. Dusser D., Bravo M. L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27(3): 547–55.
  65. Vincken W., van Noord J. A., Greefhorst A. P., Bantje T. A., Kesten S., Korducki L. et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotopium. Eur. Respir. J. 2002; 19(2): 209–16.
  66. Casaburi R., Mahler D. A., Jones P. W., Wanner A., San P. G., ZuWallack R. L. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19(2): 217–24.
  67. D’Urzo A., Ferguson G. T., van Noord J. A., Hirata K., Martin C., Horton R. et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res. 2011; 12: 156.
  68. Kerwin E., Hébert J., Gallagher N., Martin C., Overend T., Alagappan V. K. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40(5): 1106–14.
  69. Jones P. W., Singh D., Bateman E. D., Agusti A., Lamarca R., de Miquel G. et al. Efficacy and safety of treatment with twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40(4): 830–6.
  70. Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv. Ther. 2013; 30(4): 354–68.
  71. Decramer M. L., Chapman K. R., Dahl R., Frith P., Devouassoux G.,Fritscher C. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel group study. Lancet Respir. Med. 2013; 1(7): 524–33.
  72. Oba Y., Sarva S. T., Dias S. Efficacy and safety of long-acting -agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016; 71(1): 15–25.
  73. Wedzicha J. A., Decramer M., Ficker J. H., Niewoehner D. E., Sandstrom T., Taylor A. F. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1(3): 199–209.
  74. Banerji D., Fedele M. J., Chen H., Kim H. J. Dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Respirology. 2013; 18 (suppl. 4): S1–81.
  75. Wedzicha J. A., Banerji D., Chapman K. R., Vestbo J., Roche N., Ayers R. T. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374(23): 2222–34.
  76. Buhl R., Maltais F., Abrahams R., Bjermer L., Derom E., Ferguson G. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015; 45(4): 969–79.
  77. Singh D., Jones P. W., Bateman E. D., Korn S., Serra C., Molins E. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm. Med. 2014; 14: 178.
  78. D’Urzo A. D., Rennard S. I., Kerwin E. M., Mergel V., Leselbaum A. R., Caracta C. F. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir. Res. 2014; 15: 123.
  79. Bateman E. D., Chapman K. R., Singh D., D’Urzo A. D., Molins E., Leselbaum A. et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir. Res. 2015; 16: 92.
  80. Vogelmeier C., Paggiaro P. L., Dorca J., Sliwinski P., Mallet M., Kirsten A. M. et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur. Respir. J. 2016; 48(4): 1030–9.
  81. Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2014; 2(6): 472–86.
  82. Suissa S., Barnes P. J. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 2009; 34(1): 13–6.
  83. Postma D. S., Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur. Respir. J. 2009; 34(1): 10–2.
  84. Barnes N. C., Qiu Y.-S., Pavord I. D., Parker D., Davis P. A., Zhu J. et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173(7): 736–43.
  85. Barnes P. J., Adcock I. M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25(3): 552–63.
  86. Ito K., Ito M., Elliott W. M., Cosio B., Caramori G., Kon O. M. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 2005; 352(19): 1967–76.
  87. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320(7245): 1297–303.
  88. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive disease. Eur. Respir. J. 2003; 21(1): 74–81.
  89. Calverley P. M., Boonsawat W., Cseke Z., Zhong N., Peterson S., Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22(6): 912–9.
  90. Halpin D. M. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int. J. Clin. Pract. 2005; 59(10): 1187–94.
  91. Wedzicha J. A., Singh D., Vestbo J., Paggiaro P. L., Jones P. W., Bonnet-Gonod F. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108(8): 1153–62.
  92. Dransfield M. T., Bourbeau J., Jones P. W., Hanania N. A., Mahler D. A., Vestbo J. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel group, randomised controlled trials. Lancet Respir. Med. 2013; 1(3): 210–23.
  93. Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22(1): 92–100.
  94. Ernst P., Saad N., Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur. Respir. J. 2015; 45(2): 525–37.
  95. Yawn B. P., Li Y., Tian H., Zhang J., Arcona S., Kahler K. H. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 295–304.
  96. Kaplan A. G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int. J. COPD. 2015; 10: 2535–48.
  97. Antoniu S. A. New therapeutic options in the management of COPD — focus on roflumilast. Int. J. Chron. Obstruct. Pulmon. Dis. 2011; 6: 147–55.
  98. Calverley P. M., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L. M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176(2): 154–61.
  99. Calverley P. M., Rabe K. F., Goehring U. M., Kristiansen S., Fabbri L. M., Martinez F. J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374(9691): 685–94.
  100. Rennard S. I., Calverley P. M. A., Goehring U. M., Bredenbröker D., Martinez F. J. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respiratory Research. 2011; 12: 18.
  101. Bateman E. D., Rabe K. F., Calverley P. M., Goehring U. M., Brose M., Bredenbröker D. et al. Roflumilast with long-acting 2-agonists for COPD: influence of exacerbation history. Eur. Respir. J. 2011; 38(3): 553–60.
  102. Martinez F. J., Calverley P. M., Goehring U. M., Brose M., Fabbri L. M., Rabe K. F. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015; 385(9971): 857–66.
  103. Martinez F. J., Rabe K. F., Sethi S., Pizzichini E., McIvor A., Anzueto A. et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am. J. Respir. Crit. Care Med. 2016; 194(5): 559–67.
  104. Kanoh S., Rubin B. K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010; 23(3): 590–615.
  105. Albert R. K., Connett J., Bailey W. C., Casaburi R., Cooper J. A. Jr., Criner G. J. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365(8): 689–98.
  106. Uzun S., Djamin R. S., Kluytmans J. A. J., Mulder P. G. H., van’t Veer N. E., Ermens A. A. et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2014; 2(5): 361–8.
  107. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. 1996; 153(5): 1530–5.
  108. Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir. J. 1995; 8(8): 1333–8.
  109. Zheng J. P., Kang J., Huang S. G., Chen P., Yao W. Z., Yang L. et al. Effect of carbocisteine on acute exacerbation of chronic obstrucitve pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371(9629): 2013–8.
  110. Yasuda H., Yamaya M., Sasaki T., Inoue D., Nakayama K., Tomita N. et al. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2006; 54(2): 378–80.
  111. Macciò A., Madeddu C., Panzone F., Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin. Pharmacother. 2009; 10(4): 693–703.
  112. Tse H. N., Raiteri L., Wong K. Y., Yee K. S., Ng L. Y., Wai K. Y. et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013; 144(1): 106–18.
  113. Zheng J. P., Wen F. Q., Bai C. X., Wan H. Y., Kang J., Chen P. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2(3): 187–94.
  114. Cazzola M., Calzetta L., Page C., Jardim J., Chuchalin A. G., Rogliani P. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015; 24(137): 451–61.
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
N.G. Bagdasaryan, G.S. Ayvazyan, L.A. Avetisyan, N.R. Mnatsakanyan, L.T. Aleksanyan
Hemophagocytic Lymphohistiocytosis in Children
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)

News